1. Market Research
  2. > M et P Pharma AG - Product Pipeline Review - 2013

M et P Pharma AG - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

M et P Pharma AG - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “M et P Pharma AG - Product Pipeline Review - 2013” provides data on the M et P Pharma AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, M et P Pharma AG’s corporate website, SEC filings, investor presentations and featured press releases, both from M et P Pharma AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- M et P Pharma AG - Brief M et P Pharma AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of M et P Pharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of M et P Pharma AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the M et P Pharma AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate M et P Pharma AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of M et P Pharma AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the M et P Pharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with M et P Pharma AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of M et P Pharma AG and identify potential opportunities in those areas.

Table Of Contents

M et P Pharma AG - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
M et P Pharma AG Snapshot 5
M et P Pharma AG Overview 5
Key Information 5
Key Facts 5
M et P Pharma AG - Research and Development Overview 6
Key Therapeutic Areas 6
M et P Pharma AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
M et P Pharma AG - Pipeline Products Glance 10
M et P Pharma AG - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
M et P Pharma AG - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
M et P Pharma AG - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
M et P Pharma AG - Drug Profiles 14
TBS-1 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
TBS-2 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
dopamine hydrochloride 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
progesterone 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
pregnenolone succinate 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
M et P Pharma AG - Pipeline Analysis 21
M et P Pharma AG - Pipeline Products by Therapeutic Class 21
M et P Pharma AG - Pipeline Products by Target 23
M et P Pharma AG - Pipeline Products by Route of Administration 24
M et P Pharma AG - Pipeline Products by Molecule Type 25
M et P Pharma AG - Pipeline Products by Mechanism of Action 26
M et P Pharma AG - Recent Pipeline Updates 27
M et P Pharma AG - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33



List of Tables

M et P Pharma AG, Key Information 5
M et P Pharma AG, Key Facts 5
M et P Pharma AG - Pipeline by Indication, 2013 7
M et P Pharma AG - Pipeline by Stage of Development, 2013 8
M et P Pharma AG - Monotherapy Products in Pipeline, 2013 9
M et P Pharma AG - Pre-Registration, 2013 10
M et P Pharma AG - Phase II, 2013 11
M et P Pharma AG - Phase I, 2013 12
M et P Pharma AG - Preclinical, 2013 13
M et P Pharma AG - Pipeline by Therapeutic Class, 2013 22
M et P Pharma AG - Pipeline by Target, 2013 23
M et P Pharma AG - Pipeline by Route of Administration, 2013 24
M et P Pharma AG - Pipeline by Molecule Type, 2013 25
M et P Pharma AG - Pipeline Products by Mechanism of Action, 2013 26
M et P Pharma AG - Recent Pipeline Updates, 2013 27



List of Figures

M et P Pharma AG - Pipeline by Top 10 Indication, 2013 7
M et P Pharma AG - Pipeline by Stage of Development, 2013 8
M et P Pharma AG - Monotherapy Products in Pipeline, 2013 9
M et P Pharma AG - Pipeline by Top 10 Therapeutic Class, 2013 21
M et P Pharma AG - Pipeline by Top 10 Target, 2013 23
M et P Pharma AG - Pipeline by Top 10 Route of Administration, 2013 24
M et P Pharma AG - Pipeline by Top 10 Molecule Type, 2013 25
M et P Pharma AG - Pipeline Products by Top 10 Mechanism of Action, 2013 26



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.